Gemcitabine and paclitaxel suppress the production of vascular endothelial growth factor induced by deferoxamine in human non-small cell lung cancer A549 cells

Experimental and Therapeutic Medicine

Volumn 1, Issue 5, 2010, Pages 853-857

  Ikeda, Ryuji ^a   Vermeulen, Lee C ^b   Jiang, Zhisheng ^c   Lau, Elim ^a   Kolesar, Jill M ^a  

^a KAGOSHIMA UNIVERSITY   (Japan)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Gemcitabine; Paclitaxel; Vascular endothelial growth factor

Indexed keywords

CISPLATIN; DEFEROXAMINE; ERLOTINIB; GEMCITABINE; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; TUMOR GROWTH;

EID: 77955201902     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2010.130     Document Type: Article

References (33)

1. Crabb SJ, Patsios D, Sauerbrei E, Ellis PM, Arnold A, Goss G, Leighl NB, Shepherd FA, Powers J, Seymour L and Laurie SA: Tumor cavitation: impact on objective response evaluation in trials of angiogenesis inhibitors in non-small-cell lung cancer. JClin Oncol 27: 404-410, 2009.
2. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
3. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27: 6251-6266, 2009.
4. Hanahan D and Weinberg RA: The hallmarks of cancer. Cell 100: 57-70, 2000.
5. Dudek AZ and Mahaseth H: Circulating angiogenic cytokines in patients with advanced non-small cell lung cancer: correlation with treatment response and survival. Cancer Invest 23: 193-200, 2005.
6. Laack E, Scheffler A, Burkholder I, Boeters I, Andritzky B, Schuch G, Görn M, Vohwinkel G, Edler L, Fiedler W and Hossfeld DK: Pretreatment vascular endothelial growth factor (VEGF) and matrix metalloproteinase-9 (MMP-9) serum levels in patients with metastatic non-small cell lung cancer (NSCLC). Lung Cancer 50: 51-58, 2005.
7. Nishi M, Abe Y, Tomii Y, Tsukamoto H, Kijima H, Yamazaki H, Ohnishi Y, Iwasaki M, Inoue H, Ueyama Y and Nakamura M: Cell binding isoforms of vascular endothelial growth factor-A(VEGF189) contribute to blood flow-distant metastasis of pulmonary adenocarcinoma. Int JOncol 26: 1517-1524, 2005.
8. Seto T, Higashiyama M, Funai H, Imamura F, Uematsu K, Seki N, Eguchi K, Yamanaka T and Ichinose Y: Prognostic value of expression of vascular endothelial growth factor and its flt-1 and KDR receptors in stage Inon-small-cell lung cancer. Lung Cancer 53: 91-96, 2006.
9. Shimanuki Y, Takahashi K, Cui R, Hori S, Takahashi F, Miyamoto H and Fukurchi Y: Role of serum vascular endothelial growth factor in the prediction of angiogenesis and prognosis for non-small cell lung cancer. Lung 183: 29-42, 2005.
10. Wagstaff AJ, Keam SJ and McCormack PL: Bevacizumab plus platinum-based chemotherapy: in advanced non-small cell lung cancer. BioDrugs 23: 187-196, 2009.
11. Dai M, Luo RC, Zheng DY, Lü CW and Ding XM: Effects of bevacizumab and cisplatin on human lung adenocarcinoma A549/DDPxenografts in nude mice. Nan Fang Yi Ke Da Xue Xue Bao 27: 1402-1405, 2007.
12. Lee FY, Covello KL, Castaneda S, Hawken DR, Kan D, Lewin A, Wen ML, Ryseck RP, Fairchild CR, Fargnoli J and Kramer R: Synergistic antitumor activity of ixabepilone (BMS-247550) plus bevacizumab in multiple in vivo tumor models. Clin Cancer Res 14: 8123-8131, 2008.
13. Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P, Johnson BE and Heymach JV: Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 28: 193-201, 2010.
14. Jiang BH, Agani F, Passaniti A and Semenza GL: V-SRCinduces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression. Cancer Res 57: 5328-5335, 1997.
15. Rak J, Filmus J, Finkenzeller G, Grugel S, Marme D and Kerbel RS: Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev 14: 263-277, 1995.
16. Semenza GL: Hypoxia, clonal selection, and the role of HIF-1 in tumor progression. Crit Rev Biochem Mol Biol 35: 71-103, 2000.
17. López-Barneo J, del Toro R, Levitsky KL, Chiara MD and Ortega-Sáenz P: Regulation of oxygen sensing by ion channels. JAppl Physiol 96: 1187-1195, 2004.
18. Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD and Semenza GL: Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 16: 4604-4613, 1996.
19. Ferrara N and Bunting S: Vascular endothelial growth factor, a specific regulator of angiogenesis. Curr Opin Nephrol Hypertens 5: 35-44, 1996.
20. Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1: 27-31, 1995.
21. Neufeld G, Cohen T, Gengrinovitch S and Poltorak Z: Vascular endothelial growth factor (VEGF) and its receptors. FASEB J13: 9-22, 1999.
22. Carmeliet P, Moons L, Dewerchin M, Mackman N, Luther T, Breier G, Ploplis V, Muller M, Nagy A, Plow E, Gerard R, Edgington T, Risau W and Collen D: Insights in vessel development and vascular disorders using targeted inactivation and transfer of vascular endothelial growth factor, the tissue factor receptor, and the plasminogen system. Ann NYAcad Sci 811: 191-206, 1997.
23. Ferrara N, Carver-Moore K, Chen H, Dowd M, Lu L, O'Shea KS, Powell-Braxton L, Hillan KJ and Moore MW: Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature 380: 439-442, 1996.
24. Olson TA, Mohanraj D, Carson LF and Ramakrishnan S: Vascular permeability factor gene expression in normal and neoplastic human ovaries. Cancer Res 54: 276-280, 1994.
25. Senger DR, van de Water L, Brown LF, Nagy JA, Yeo KT, Yeo TK, Berse B, Jackman RW, Dvorak AM and Dvorak HF: Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer Metastasis Rev 12: 303-324, 1993.
26. Holash J, Davis S, Papadopoulos N, et al: VEGF-Trap: a VEGF blocker with potent antitumor effects. Proc Natl Acad Sci USA99: 11393-11398, 2002.
27. Kim KJ, Li B, Winer J, Armanini M, Gillett N, Phillips HS and Ferrara N: Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362: 841-844, 1993.
28. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Bohlen P and Hicklin DJ: Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Cancer Res 59: 5209-5218, 1999.
29. Loo WT, Fong JH, Cheung MN and Chow LW: The efficacy of paclitaxel on solid tumour analysed by ATPbioluminescence assay and VEGF expression: a translational research study. Biomed Pharmacother 59 (Suppl 2): 337-339, 2005.
30. Plunkett W, Huang P, Xu YZ, Heinemann V, Grunewald R and Gandhi V: Gemcitabine: metabolism, mechanisms of action, and self-potentiation. Semin Oncol 22: 3-10, 1995.
31. Krause S, Förster Y, Kraemer K, Fuessel S, Kotzsch M, Schmidt U, Wirth MP, Meye A and Schwenzer B: Vascular endothelial growth factor antisense pretreatment of bladder cancer cells significantly enhances the cytotoxicity of mitomycin C, gemcitabine and cisplatin. JUrol 174: 328-331, 2005.
32. Förster Y, Meye A, Krause S and Schwenzer B: Antisense-mediated VEGF suppression in bladder and breast cancer cells. Cancer Lett 212: 95-103, 2004.
33. Maxwell PH and Ratcliffe PJ: Oxygen sensors and angiogenesis. Semin Cell Dev Biol 13: 29-37, 2002.